Signage exterior Johnson & Johnson workplaces in Irvine, California, US, on Friday, Oct. 10, 2025.
Kyle Grillot | Bloomberg | Getty Photos
Johnson & Johnson on Wednesday mentioned the U.S. Meals and Drug Administration accepted its once-daily psoriasis tablet, the primary oral choice to rival best-selling pictures.
The FDA accepted the tablet, Icotyde, to deal with average to extreme plaque psoriasis, an autoimmune situation that causes tough patches of pores and skin. Sufferers sometimes begin therapy with topical drugs.
If these do not work, they advance to drugs or pictures. J&J sees Icotyde turning into the first-line systematic therapy for psoriasis, in between topicals and pictures.
Drugmakers have been growing extra superior medicines than commonplace topicals, turning psoriasis right into a extremely aggressive area. Icotyde targets the identical IL-23 receptor as best-selling pictures like J&J’s Tremfya and AbbVie‘s Skyrizi, giving sufferers an oral different to among the most superior — and costliest — medication available on the market.
“To have the ability to to have the ability to have one thing that’s comparatively easy, that provides that degree of clearance, trusted security profile, and in a easy tablet, we expect goes to be revolutionary,” mentioned Jennifer Taubert, chairman of J&J Progressive Medication.
J&J estimates about 8 million individuals within the U.S. have plaque psoriasis, and that 75% of individuals do not advance from topicals to pictures due to causes like fearing needles. Taubert sees Icotyde interesting to these sufferers.
“We consider having the kind of profile that Icotyde has in a easy, once-daily oral tablet, we expect it is going to be an absolute sport changer for sufferers,” Taubert mentioned.
J&J hasn’t introduced how a lot Icotyde will value past saying the corporate will assist individuals pay for the drugs. Rival pictures Tremfya and Skyrizi value round $100,000 a yr.
J&J sees peak annual gross sales of Icotyde exceeding $5 billion as soon as it is accepted for different autoimmune circumstances. It is testing the drug for psoriatic arthritis, ulcerative colitis and Crohn’s illness.
Shares of J&J slid one-quarter of a p.c Wednesday whereas shares of Skyrizi-maker AbbVie fell greater than 4%. Protagonist Therapeutics, a biotech firm that developed Icotyde with J&J, was buying and selling about flat.
